Scarica l'app Stockscreener
30.08
0.56%
-0.17
Dopo l'orario di chiusura:
30.26
0.18
+0.60%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché TEVA Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$30.25
Aprire:
$29.45
Volume 24 ore:
2.84M
Relative Volume:
0.33
Capitalizzazione di mercato:
$35.03B
Reddito:
$17.41B
Utile/perdita netta:
$1.43B
Rapporto P/E:
24.69
EPS:
1.2182
Flusso di cassa netto:
$1.00B
1 W Prestazione:
+1.01%
1M Prestazione:
-10.93%
6M Prestazione:
+50.02%
1 anno Prestazione:
+96.73%
Intervallo 1D:
$29.40
$30.35
Intervallo di 1 settimana:
$28.29
$30.71
Portata 52W:
$12.46
$37.34
Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Company Profile
Nome
Teva Pharmaceutical Industries Ltd Adr
Settore
Telefono
972 (3) 914-8213
Indirizzo
TEVA PHARMACEUTICAL INDUSTRIES LIMITED, TEL AVIV
Compare TEVA vs TAK, ZTS, HLN, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
30.08 | 35.03B | 17.41B | 1.43B | 1.00B | 1.2182 |
TAK
Takeda Pharmaceutical Co Adr
|
18.74 | 59.20B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
117.94 | 49.79B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.93 | 44.27B | 14.54B | 2.22B | 2.58B | 0.4871 |
UTHR
United Therapeutics Corp
|
564.81 | 24.75B | 3.18B | 1.33B | 1.04B | 27.90 |
Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-09 | Iniziato | Barclays | Overweight |
| 2025-12-05 | Iniziato | Scotiabank | Sector Outperform |
| 2025-06-06 | Iniziato | Goldman | Buy |
| 2025-05-28 | Iniziato | Truist | Buy |
| 2025-05-12 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-07-10 | Aggiornamento | Argus | Hold → Buy |
| 2024-03-08 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2024-02-12 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2024-01-23 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-01-03 | Aggiornamento | Piper Sandler | Underweight → Neutral |
| 2023-12-18 | Iniziato | HSBC Securities | Buy |
| 2023-11-27 | Aggiornamento | UBS | Neutral → Buy |
| 2023-07-06 | Aggiornamento | UBS | Sell → Neutral |
| 2023-05-25 | Iniziato | Morgan Stanley | Equal-Weight |
| 2023-05-18 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2023-01-19 | Downgrade | Jefferies | Buy → Hold |
| 2022-11-14 | Downgrade | JP Morgan | Neutral → Underweight |
| 2022-11-04 | Downgrade | UBS | Neutral → Sell |
| 2022-10-21 | Ripresa | Jefferies | Buy |
| 2022-08-05 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-06-14 | Ripresa | UBS | Neutral |
| 2022-05-17 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-05-04 | Downgrade | Piper Sandler | Neutral → Underweight |
| 2022-04-05 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2022-03-25 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2022-01-27 | Downgrade | Argus | Buy → Hold |
| 2021-10-28 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2021-05-04 | Downgrade | UBS | Buy → Neutral |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2020-11-25 | Iniziato | Oppenheimer | Perform |
| 2020-08-06 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2020-07-27 | Ripresa | Goldman | Neutral |
| 2020-06-01 | Aggiornamento | SunTrust | Hold → Buy |
| 2020-04-24 | Ripresa | Citigroup | Neutral |
| 2020-04-06 | Aggiornamento | UBS | Neutral → Buy |
| 2020-02-24 | Downgrade | Edward Jones | Hold → Sell |
| 2019-11-12 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2019-10-17 | Aggiornamento | Gabelli & Co | Hold → Buy |
| 2019-08-07 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-07-19 | Iniziato | Wolfe Research | Peer Perform |
| 2019-07-15 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2019-07-10 | Ripresa | Credit Suisse | Neutral |
| 2019-07-05 | Aggiornamento | Argus | Hold → Buy |
| 2019-06-11 | Iniziato | Barclays | Underweight |
| 2019-06-03 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2019-05-30 | Downgrade | BofA/Merrill | Buy → Underperform |
| 2019-05-28 | Downgrade | UBS | Buy → Neutral |
| 2019-03-20 | Iniziato | SunTrust | Hold |
| 2019-03-07 | Ripresa | UBS | Buy |
Mostra tutto
Teva Pharmaceutical Industries Ltd Adr Borsa (TEVA) Ultime notizie
Assessing Teva Pharmaceutical Industries (TEVA) Valuation After New Biosimilar Approvals And Pipeline Progress - Sahm
Viatris at $14: A Double-Digit FCF Yield Hiding in Plain Sight - Investing.com
Missile Strike Tests Teva Supply Resilience And Biosimilar Growth Plans - Sahm
Price to sales ratio of Teva Pharmaceutical Industries Limited Sponsored ADR – BSESOF:TEV - TradingView
Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI™ (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair® (omalizumab) - Sahm
ETFs Investing in Teva Pharmaceutical Industries Limited Sponsored ADR Stocks - TradingView
How Investors May Respond To Teva (TEVA) Advancing TEV ‘325 In Biologics For Inflammatory Diseases - Sahm
Assessing Teva Pharmaceutical Industries (NYSE:TEVA) Valuation After Recent Share Price Weakness - Sahm
TEVA Stock Price, Quote & Chart | TEVA PHARMACEUTICAL-SP ADR (NYSE:TEVA) - ChartMill
Teva Pharmaceutical Industries Limited Sponsored ADR Trade Ideas — LS:883035 - TradingView
Teva Releases Q1 2026 Aide Memoire - Sahm
Will Teva’s (TEVA) Olanzapine LAI Milestone and Legal Win Change Its Innovation-Led Narrative? - Sahm
Tesla Upgraded, Super Micro Computer Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
A Look At Teva Pharmaceutical Industries (NYSE:TEVA) Valuation After Branded Drugs Pass $1b Quarterly Revenue - Sahm
How Teva’s Blackstone-Backed ‘Pivot to Growth’ Strategy Could Reshape Teva Pharmaceutical Industries (TEVA) Investors - Sahm
Assessing Teva Pharmaceutical Industries (NYSE:TEVA) Valuation After Pivot To Growth Update At Leerink Conference - Sahm
Teva Blackstone Duvakitug Deal Tests Growth Story And Concentration Risk - Sahm
Teva Drug Updates Support Branded Growth Story And Valuation Upside Potential - Sahm
What's Driving the Market Sentiment Around Teva Pharmaceutical Industries Ltd? - Sahm
Duvakitug IBD Data and TEV-749 Filing Might Change The Case For Investing In Teva (TEVA) - Sahm
Teva to Present at the Upcoming Investor Conferences in March - Sahm
J&J Stock Up 38% in 6 Months: Should You Buy, Sell or Hold? - Finviz
Where is Teva Pharmaceutical Industries Limited (TEVA) Headed? - Finviz
Corcept's Q4 Earnings and Revenues Fall Short of Estimates - Finviz
FDA Accepts Teva's New Long-Acting Schizophrenia Treatment Application - Sahm
Assessing Teva Pharmaceutical Industries (NYSE:TEVA) Valuation After Its Strong Recent Share Price Momentum - Sahm
Truist Boosts Teva (TEVA) Stock Target Amid Pipeline Growth Opportunities - Finviz
Corcept Therapeutics Stock Plunges As Court Clears Teva Generic - Sahm
Goldman Sachs See Teva Pharmaceutical Industries Limited (TEVA) Driving Double-Digit Earnings Growth Through 2026 - Finviz
Teva Pharmaceutical Industries Ltd (TEVA) Stock Price, Trades & News - GuruFocus
Teva’s Duvakitug Data Puts Ulcerative Colitis And Crohn’s Bet In Focus - Sahm
Should You Invest in Teva Pharmaceutical (TEVA), Here's What the Street Has to Say - Finviz
Teva (TEVA) Is Down 5.2% After Returning To Profitability On Innovation-Led Revenue Shift – What’s Changed - Sahm
Teva Pharmaceutical Industries (NYSE:TEVA) Valuation In Focus Amid Momentum - Kalkine Media
Here's What Analysts Are Saying About Teva Pharmaceutical (TEVA) Post Earnings - Finviz
Assessing Teva Pharmaceutical Industries (NYSE:TEVA) Valuation After Recent Share Price Momentum And Biosimilar Growth Hopes - Sahm
A Look Into Teva Pharmaceutical Indus Inc's Price Over Earnings - Sahm
Barclays Raises Teva Pharmaceutical (TEVA) PT to $38 Following Strong Q4 Earnings Beat - Finviz
Teva Canada Announces Approval of Expanded Indication of [Pr]AJOVY® (fremanezumab solution for subcutaneous injection), the First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine - Sahm
Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory - Finviz
Teva Canada Mayzent Deal Supports Neuroscience Focus And Valuation Debate - Sahm
FedEx Upgraded, Costco Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Earnings call transcript: Teva Q4 2025 earnings beat expectations, stock rises - Investing.com
Assessing Teva Pharmaceutical Industries’ Valuation After Strong 2025 Earnings And Analyst Upgrades - Sahm
Teva Pharmaceutical Industries Ltd Adr Azioni (TEVA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.40%
0.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):